IMO, I think this is a good question. I thought about this yesterday when the board was discussing the possibility of the BLA being delayed and a non-binding agreement being signed. I’m assuming the first milestone payment for the non-binding agreement will be correlated to submission of the BLA. Obviously, if the BLA is delayed, CYDY will need more short term financing to get the BLA submitted.
And yes, he clearly stated he expects revenues in 2Q 2020, but that doesn’t mean the BLA won’t be delayed for another month or two.
Honestly, I don’t think there is anyway to know until we hear NP discuss the “minutes” from the FDA call on Thursday. But given it’s the FDA, it’s likely there could be another delay and need for short term financing.